Biogen Inc. (BIIB) EVP Adriana Karaboutis Sells 380 Shares
Biogen Inc. (NASDAQ:BIIB) EVP Adriana Karaboutis sold 380 shares of the company’s stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $313.00, for a total transaction of $118,940.00. Following the completion of the transaction, the executive vice president now directly owns 7,172 shares in the company, valued at approximately $2,244,836. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Biogen Inc. (NASDAQ:BIIB) opened at 311.48 on Wednesday. Biogen Inc. has a 52 week low of $223.02 and a 52 week high of $333.65. The stock’s 50 day moving average price is $309.05 and its 200-day moving average price is $278.92. The company has a market capitalization of $68.25 billion, a PE ratio of 18.19 and a beta of 0.95.
Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Thursday, July 21st. The biotechnology company reported $5.21 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.69 by $0.52. The business had revenue of $2.89 billion for the quarter, compared to analysts’ expectations of $2.79 billion. Biogen had a net margin of 33.97% and a return on equity of 40.59%. The company’s revenue was up 11.7% compared to the same quarter last year. During the same quarter last year, the company posted $4.22 EPS. On average, equities research analysts predict that Biogen Inc. will post $20.10 earnings per share for the current fiscal year.
Several research firms have recently weighed in on BIIB. Credit Suisse Group AG set a $322.00 price target on shares of Biogen and gave the stock a “hold” rating in a report on Sunday, September 18th. Vetr cut shares of Biogen from a “buy” rating to a “hold” rating and set a $321.54 price target on the stock. in a report on Tuesday. Zacks Investment Research cut shares of Biogen from a “buy” rating to a “hold” rating in a report on Tuesday, July 12th. Morgan Stanley reaffirmed a “buy” rating and issued a $385.00 price target on shares of Biogen in a report on Wednesday, August 3rd. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Biogen in a report on Wednesday, June 8th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. Biogen currently has an average rating of “Buy” and an average target price of $346.36.
Hedge funds and other institutional investors have recently modified their holdings of the company. Los Angeles Capital Management & Equity Research Inc. boosted its position in shares of Biogen by 9.5% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,909 shares of the biotechnology company’s stock valued at $1,018,000 after buying an additional 338 shares in the last quarter. Howard Hughes Medical Institute acquired a new position in shares of Biogen during the first quarter valued at $135,000. Massmutual Trust Co. FSB ADV boosted its position in shares of Biogen by 6.5% in the first quarter. Massmutual Trust Co. FSB ADV now owns 2,585 shares of the biotechnology company’s stock valued at $673,000 after buying an additional 157 shares in the last quarter. Columbia Partners L L C Investment Management boosted its position in shares of Biogen by 0.3% in the first quarter. Columbia Partners L L C Investment Management now owns 9,540 shares of the biotechnology company’s stock valued at $2,483,000 after buying an additional 26 shares in the last quarter. Finally, Provident Investment Management Inc. boosted its position in shares of Biogen by 4.9% in the first quarter. Provident Investment Management Inc. now owns 64,899 shares of the biotechnology company’s stock valued at $16,895,000 after buying an additional 3,004 shares in the last quarter. Institutional investors and hedge funds own 86.21% of the company’s stock.
Biogen Inc, formerly Biogen Idec Inc, is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis.
Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.